ANI Pharmaceuticals, Inc.'s (ANIP) CEO Nikhil Lalwani on Q3 2020 Results - Earnings Call Transcript

SA Transcripts
153.96K Followers

Q3: 2020-11-05 Earnings Summary

EPS of $0.97 beats by $0.09
 | Revenue of $52.98M (3.20% Y/Y) beats by $1.48M

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q3 2020 Results Earnings Conference Call November 5, 2020 10:30 AM ET

Company Participants

Lisa Wilson - In-Site Communications, IR
Nikhil Lalwani - President and CEO
Stephen Carey - Chief Financial Officer

Conference Call Participants

Dana Flanders - Guggenheim
Elliot Wilbur - Raymond James
Brandon Folkes - Cantor Fitzgerald

Operator

Good morning. And welcome to today’s program. My name is Nicole, and I will be your conference operator. At this time, I would like to welcome everyone to the ANI Pharmaceuticals Third Quarter 2020 Earnings Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer period. [Operator Instructions]

As a reminder, this call is being recorded today, November 5, 2020. It is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for ANI Pharmaceuticals. Please go ahead.

Lisa Wilson

Thank you, Operator. Welcome to ANI Pharmaceuticals Q3 2020 earnings results call. This is Lisa Wilson of In-Site Communications, Investor Relations for ANI. With me on today’s call are Nikhil Lalwani, our new President and Chief Executive Officer; and Stephen Carey, Chief Financial Officer of ANI. You can also access the webcast of this call through the Investors section of the ANI website at anipharmaceuticals.com.

Before we get started, I would like to remind everyone that any statements made on today’s conference call that express a belief, expectation, projection, forecast, anticipation or intent regarding future events and the company’s future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act.

These forward-looking statements are based on information available to ANI Pharmaceuticals’ management as of today, and involve risks and uncertainties, including those noted in our press release issued this morning and our filings with the SEC.

Recommended For You

About ANIP Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ANIP